四環醫藥(yao)(yao)控股(gu)集團(tuan)有(you)限(xian)公(gong)司宣(xuan)布，集團(tuan)旗下非(fei)全(quan)資(zi)(zi)(zi)附屬公(gong)司吉(ji)(ji)林(lin)(lin)惠(hui)升(sheng)生(sheng)(sheng)物制藥(yao)(yao)有(you)限(xian)公(gong)司已成功完成由吉(ji)(ji)林(lin)(lin)百(bai)興百(bai)榮投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)中心、吉(ji)(ji)林(lin)(lin)省(sheng)股(gu)權基金投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)有(you)限(xian)公(gong)司、吉(ji)(ji)林(lin)(lin)省(sheng)科技投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)基金有(you)限(xian)公(gong)司及無錫尚惟創業(ye)投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)合伙企(qi)業(ye)作(zuo)為(wei)A+輪(lun)投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)人(ren)(ren)(ren)以增(zeng)資(zi)(zi)(zi)方式(shi)進行的A+輪(lun)融資(zi)(zi)(zi)。根(gen)據本(ben)次增(zeng)資(zi)(zi)(zi)協議，A+輪(lun)投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)人(ren)(ren)(ren)以人(ren)(ren)(ren)民幣(bi)(bi)580,000,000元（相當于港幣(bi)(bi)約650,000,000元）的代價(jia)認購惠(hui)升(sheng)生(sheng)(sheng)物新(xin)增(zeng)注冊資(zi)(zi)(zi)本(ben)人(ren)(ren)(ren)民幣(bi)(bi)38,666,667元。本(ben)次增(zeng)資(zi)(zi)(zi)結(jie)束后，惠(hui)升(sheng)生(sheng)(sheng)物的注冊資(zi)(zi)(zi)本(ben)增(zeng)加至人(ren)(ren)(ren)民幣(bi)(bi)37,200萬元，整體(ti)投(tou)(tou)(tou)(tou)后估值(zhi)為(wei)人(ren)(ren)(ren)民幣(bi)(bi)55.8億元，其中集團(tuan)所占惠(hui)升(sheng)生(sheng)(sheng)物的股(gu)權比例約為(wei)61.29%，A+輪(lun)投(tou)(tou)(tou)(tou)資(zi)(zi)(zi)人(ren)(ren)(ren)共占惠(hui)升(sheng)生(sheng)(sheng)物的股(gu)權比例為(wei)10.4%。(醫藥(yao)(yao)健聞)